Penetrium Bioscience: 투자판단관련주요경영사항(임상시험계획승인신청등결정) (재발성 또는 불응성 진행성 고형암 임상 2a상 임상시험계획 숭인)
AI reading
★★★ Bullish · Material event
고형암 대상 임상 2a상 미국 FDA 승인
An AI model read the opening section of the filing and rated it relative to the company's size. It can be wrong, so check the original filing on DART (Korean).
Other filings by Penetrium Bioscience
For information only. Not investment advice.